Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q2 2020 · 10-Q
Revenue$44.63K$44.63K−28.9% vs Q2 2019 Net Income-$1.63M-$1.63MN/M vs Q2 2019 EPS Diluted-$0.17-$0.17N/M vs Q2 2019 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flowderived-$154,846N/M Margins · derivedGross margin74.7%+21.8 pt vs Q2 2019
Operating margin-1348.4%+205.6 pt vs Q2 2019
Net margin-3662.6%+8831.7 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 19, 2020 · 50 d after period end